Amarin and Mochida inks deal to develop EPA-based drug products and indications

|About: Amarin Corporation PLC (AMRN)|By:, SA News Editor

Amarin Corporation (NASDAQ:AMRN) has entered into a multi-faceted collaboration with Mochida Pharmaceutical Co.

Under the agreement, Amarin obtained an exclusive license to certain Mochida intellectual property to focus on the development and commercialization of early-stage drug products and indications based on the omega-3 acid, EPA (eicosapentaenoic acid).

Financial terms are not disclosed.

Amarin shares are up 1% premarket.